1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) PAR 26-116 is sponsored by National Institutes of Health (NIH). While not directly for law students, this program funds collaborative research. Law students with a strong interest in health law, bioethics, or related fields could potentially be involved in research projects funded by this grant through an eligible institution.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 313 -- NIH Office of Research on Women's Health Last Updated: December 8, 2025 View version history on Grants.
gov The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health.
It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations...
between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting clinical research projects in collaboration with NIH intramural investigators.
Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) City or township governments Federally recognized Native American tribal governments Special district governments Public and Indian housing authorities Private institutions of higher education Independent school districts Public and state institutions of higher education For-profit organizations other than small businesses Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations.
This new requirement was effective, May 1, 2025. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding.
This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors. Grantor contact information ClinicalCtrPartner@mail. nih.
gov ClinicalCtrPartner@mail. nih. gov ClinicalCtrPartner@mail.
nih. gov File name Description Last updated PAR-26-116-Full-Announcement. html PAR-26-116-Full-Announcement.
html Link to additional information Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity :
According to the current listing, eligibility includes: Institutions of Higher Education, Nonprofits, For-profit Organizations, Government agencies. Individuals are not directly eligible, but law students at eligible institutions could participate in funded projects. Confirm the full requirements in the official notice before applying.
Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) PAR 26-116 is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article